The CAR-NK Project

Chimeric antigen receptor targeted oncoimmunotherapy with natural killer cells

CAR NK at a glance

Chimeric antigen receptor targeted oncoimmunotherapy with Natural Killer cells

Chimeric antigen receptor targeted oncoimmunotherapy with Natural Killer cells” (SMIS code 103662is a project implemented from 01.09.2016 to 31.08.2020 in the Centre for Gene and Cellular Therapies in the Treatment of Cancer – OncoGen within Pius Brinzeu Emergency Clinical County Hospital Timisoara, based on the funding contract number 32 of 01.09.2016. 

The project runs for 48 months and is co-financed by the European Regional Development Fund under Competitiveness Operational Programme 2014-2020, Priority Axis 1 „Research, Technological Development and Innovation (RDI) to support economic competitiveness and business development”, Action 1.1.4 „ Attracting high-level personnel from abroad in order to enhance the RD capacity”, Project Type „ Attracting high-level personnel from abroad”. 

The total value of the project is 8,910,531.86 RON, with a total eligible value of 8,493,897.32 RON, representing the eligible non-reimbursable financial assistance, out of which 7,172,246.90 RON from the European Regional Development Fund (ERDF) and 1,321,650.42 RON from the national budget. 

CAR-NK is implemented in partnership with the prestigious team coordinated by Prof. Torsten Tonn from the Technical University of Dresden.  

The main objective is to develop advanced personalised immunotherapies for cancer based on chimeric antigen receptor-Natural killer (NK) cells, In addition, the first human CAR-NKs cellular bank will be created. This project is implemented with the support of an international team by attracting foreign specialists with recognized competence, thus increasing the Romanian participation in research areas at European standards and creating a high-level research group in cancer therapy.